
Covid-19 vaccine for 5- to 11-year-olds is safe and shows 'robust' antibody response, Pfizer says
CNN
A Phase 2/3 trial of Pfizer/BioNTech's two-dose Covid-19 vaccine for children ages 5 to 11 showed it is safe and generated a "robust" antibody response.
These are the first such results released for this age group for a US Covid-19 vaccine, and the data has not yet been peer-reviewed or published. Pfizer said it plans to submit to the US Food and Drug Administration for emergency use authorization soon.
The trial included 2,268 participants ages 5 to 11 and used a two-dose regimen of the vaccine administered 21 days apart. This trials used a 10-microgram dose -- smaller than the 30-microgram dose that has been used for those 12 and older.

Over the past 10 days, Vice President JD Vance put Ukrainian President Volodymyr Zelensky on notice, rattled the confidence of century-old allies in Western Europe during his first foreign trip, decamped to Capitol Hill to help in delicate budget talks and delivered a spirited defense of the Trump administration’s first month to a gathering of conservatives outside the nation’s capital.